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prevalent in neuropathic pain models than for other chronic pain states. Finally the 
majority of models (eleven) used a Markov structure but four of ten neuropathic 
pain models used decision trees. ConClusions: Some methodological similarities 
can be identified when considering economic modelling within sub-populations in 
particular neuropathic pain. However, there is scope for further consensus in the key 
design attributes of pain models, in particular the choice of secondary outcomes. 
Further research is required to identify the strengths, weaknesses and complexities 
of the key modelling choices. FUNDING STATEMENT: This research was funded by 
Mundipharma International Limited.
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objeCtives: A global economic model to evaluate the cost-effectiveness of targeted 
treatment using companion diagnostics in advanced/metastatic cancer treatment 
has been recently developed. Targeted treatment with cetuximab guided with KRAS 
testing in metastatic colorectal cancer (mCRC) is well implanted and has been sub-
ject of different economic evaluations. The objective of this study was to use data on 
cetuximab guided with KRAS testing in mCRC to validate the global economic model 
in advanced/metastatic cancer. Methods: Survival data and incidence of adverse 
events (infections, rash, and pain) were obtained from the CO. 17 study, which is 
a pivotal trial on the efficacy of cetuximab used according to the KRAS status vs. 
best supportive care (BSC). Prevalence of KRAS mutation, specificity/sensitivity and 
cost of KRAS testing, and the cost of cetuximab were obtained from the literature. 
Other parameters for the cost-effectiveness analysis were intrinsic components of 
the global model. Analyses were conducted from a Ministry of Health (MoH) and a 
societal perspective. Results: The incremental cost-utility ratio (ICUR) of cetuxi-
mab treatment guided with KRAS testing compared to no testing and BSC to all 
patients from a MoH perspective was estimated at $192,814/QALY and at $297,198/
QALY from a societal perspective. According to the deterministic analysis results, 
the ICUR of cetuximab with KRAS testing compared to no testing and BSC varied 
between $149,845/QALY and $387,971/QALY from a MoH perspective and between 
$232,417/QALY and $492,354/QALY from a societal perspective. Parameters that 
have the greatest impact on base-case ICURs were the cost of cetuximab and the 
specificity of KRAS testing. ConClusions: Validation using cetuximab with KRAS 
testing suggests that the global economic model is robust, as results obtained were 
in the range than those reported in the literature. Although further validations will 
be performed, the global model appears to produce quick, but accurate estimates.
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objeCtives: Value of information (VoI) analysis helps to set priorities for future 
research by quantifying the value of collecting additional information. Determining 
whether further evidence is required is especially important in oncology, where 
novel, but expensive therapies with substantial uncertainty are emerging every 
day. We aim to provide an overview of published VoI studies within cancer medicine 
and summarize their methodological characteristics. Methods: We performed a 
systematic literature review using Pubmed to identify VoI analyses applied within 
cancer research. Studies exploring topics merely related to methodology were 
excluded. The search terms were refined following the recent publication by Tuffaha 
et al. 2014. Screening of articles was performed by two independent reviewers. 
We extracted characteristics, such as health care context, disease, and type of VoI 
analyses. Results: We identified a total of 96 references. Overall, 35 articles were 
included for analysis. Nearly one-half (16) of the studies were conducted in the 
health care context of UK, eight in the US, five in Finland, three in the Netherlands, 
and one in Canada, France and Denmark. Disease areas included breast cancer 
(26%), non-small-cell lung cancer (14%), colorectal cancer (14%), esophageal cancer 
(9%) non-Hodgkin lymphoma (6%) and prostate cancer (6%). Nearly all of the studies 
conducted expected value of perfect information (EVPI) analysis and about one-
half expected value of partial information (EVPPI). One study reported on expected 
value of individualized care, and only three studies did sample size and trial cost 
estimations. ConClusions: VoI analyses are becoming a more commonly applied 
method, following standard calculations of cost-effectiveness, to assess the value of 
further research. Simpler techniques, such as EVPI and EVPPI were reported more 
frequently compared to the computationally more demanding calculations of EVSI 
and ENBS, which often require complex statistical methods and estimates of a 
study’s costs need to be derived.
PRM95
clinical tRial siMulation considERinG Quality of lifE outcoMEs
Mohseninejad L., Heeg B., Majer I.M.
Pharmerit International, RotterdamThe Netherlands
objeCtives: Prior to the actual implementation, trial simulations are often per-
formed to optimize registration study design and hence to maximize the probability 
of marketing approval. Almost exclusively, trials focus on clinical outcomes how-
ever reimbursement submissions require health economic evidence, in particular, 
information on patients’ quality of life (QoL) and estimates of quality-adjusted life 
limitations potentially providing more accurate estimates of the cost-effectiveness. 
This study aims to explore the strengths and limitations associated with simula-
tion modelling, and the appropriateness of this methodology in ophthalmology.  
Methods: An ophthalmology model that was previously developed using a Markov 
structure was adapted to a patient simulation model using the same cost and qual-
ity of life inputs, and clinical inputs adapted to the appropriate format. The deter-
ministic and probabilistic results of each model were then compared to each other, 
with the costs being broken down by health state to identify key areas of differences. 
Each model’s results were verified against real-world observational data. Results: 
Results suggest that cost and quality of life outcomes are similar when unilateral 
disease is considered, with differences in quality of life and costs being seen when 
bilateral disease is incorporated. The key area of differences in costs is those relating 
to blindness, as this is a function of both eyes which is not captured well in a Markov 
model. One-off costs when a patient becomes blind are also not well captured in a 
Markov model. ConClusions: Our results suggest that the ability of simulation 
models to more accurately represent the real-world patient pathway allows a num-
ber of aspects of disease progression to be modelled, which cannot be easily done 
using a Markov structure. In particular, the benefits of a simulation approach can 
be demonstrated in the modelling of quality of life as a function of visual acuity in 
both eyes, and capturing the costs relating to blindness, resulting in differences in 
estimated cost effectiveness.
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objeCtives: The ONCOTYROL Prostate Cancer Outcome and Policy (PCOP) Model 
is a state-transition micro-simulation model designed to evaluate prostate cancer 
(PCa) screening. We used the model to investigate how the benefits-harm balance 
of PCa screening is affected by the size of the latent prevalence pool. For this pur-
pose, we recalibrated the natural history and detection component of the original 
PCOP model adopted from an earlier version of the Erasmus MISCAN model to 
match the higher prevalence observed by autopsy studies. The benefits and harms 
of screening predicted by the recalibrated model were then compared with predic-
tions from the original model. Methods: For recalibration, we reprogrammed the 
natural history and detection component of the PCOP model as a deterministic 
state-transition model with stage- and grade-specific cancer states in the statisti-
cal software package R. All parameters were implemented as functions or variables 
and calibrated simultaneously in a single run using the ‘nlminb’ optimization 
algorithm available in R to minimize the deviation of model predictions from 
observed data. Calibration targets were observed data from autopsy studies, cancer 
registries and the European trial (ERSPC). Both the recalibrated and original models 
were identical except for calibrated parameters. Results: In total, we calibrated 
46 parameters. Observed data could not be sufficiently fitted using the original 
set of parameters. Additional parameters, allowing for an interruption of disease 
progression in the stage- and grade-specific health states, and an effect modifier 
allowing for lower screening sensitivities in older men had to be implemented. 
Recalibration to higher prevalence demonstrated a considerable increase of over-
diagnosis and decline of screening sensitivity, which significantly worsened the 
benefit-harm balance of screening regarding QALYs. ConClusions: Benefit-harm 
predictions of models, which use calibration to simulate PCa progression in the 
unobservable latent phase, can be significantly affected by the assumptions on 
latent cancer prevalence.
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objeCtives: Economic modelling of analgesics for chronic pain (including the 
chronic pain sub-populations of musculoskeletal, neuropathic and malignant pain) 
is well established but characterised by methodological heterogeneity. The methods 
used to model pain vary substantially between and within the sub-populations 
and this variability inhibits comparability across the evidence base. This research 
aims to facilitate increased consensus for future development of pain models, by 
summarising existing published economic models and identifying key model char-
acteristics. Methods: A systematic search and methodological review of published 
economic models of therapies in chronic pain was performed. MEDLINE, EMBASE, 
Health Technology Assessment, NHS Economic Evaluation Database and EconLit 
were accessed in April 2014 and, from studies that met the inclusion criteria, key 
methodological data were extracted and analysed. Results: Thirty-four studies 
were included in the final review. From these, eighteen original model structures 
were identified. Outcomes considered alongside analgesic effect varied substantially 
across studies. Assumptions were used to model multiple treatment lines in eleven 
model structures. Only three models used a time horizon greater than one year. 
The inclusion of the costs of adverse events was common (eleven models) but less 
